Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-25

Clinical Trial Update: Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating riociguat for systemic sclerosis has completed; results posted in 2019 with data on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Riociguat (riociguat)

Snippet

Sponsor: Bayer | Conditions: Scleroderma, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2019-01-25